Methods in comparative effectiveness research

Journal of Clinical Oncology

Volumn 30, Issue 34, 2012, Pages 4208-4214

  Armstrong, Katrina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; EXPERIMENTAL STUDY; EXTERNAL VALIDITY; HORMONE SUBSTITUTION; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; INTERNAL VALIDITY; ISCHEMIC HEART DISEASE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPENSITY SCORE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC);

COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84870662623     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.2659     Document Type: Review

References (66)

1. Committee on Comparative Effectiveness Research Prioritization, Institute of Medicine: Summary: Initial National Priorities for Comparative Effectiveness Research. Washington, DC, The National Academies Press, 2009. p 29
2. Berwick DM, Nolan TW, Whittington J: The triple aim: Care, health, and cost. Health Aff (Millwood) 27:759-769, 2008
3. Brook RH: Can the Patient-Centered Outcomes Research Institute become relevant to controlling medical costs and improving value? JAMA 306:2020-2021, 2011
4. Federal Coordinating Council: Report to the President and the Congress on Comparative Effectiveness Research. http://www.hhs.gov/recovery/programs/cer/ execsummary.html
5. Sox HC, Goodman SN: The methods of comparative effectiveness research. Annu Rev Public Health 33:425-445, 2012
6. Council MR: Streptomycin treatment of pulmonary tuberculosis: A report of the Streptomycin in Tuberculosis Trials Committee. BMJ 2:769-782, 1948
7. Hill AB: Heberden oration: Reflections on the controlled trial. Ann Rheum Dis 25:107-113, 1966
8. Tepper JE, Blackstock AW: Randomized trials and technology assessment. Ann Intern Med 151:583-584, 2009
9. Luce BR, Kramer JM, Goodman SN, et al: Rethinking randomized clinical trials for comparative effectiveness research: The need for transformational change. Ann Intern Med 151:206-209, 2009
10. Hutson S: A change is in the wind as "adaptive"clinical trials catch on. Nat Med 15:977, 2009
11. Berry DA: Adaptive clinical trials in oncology. Nat Rev Clin Oncol 9:199-207, 2011
12. Berry DA: Adaptive clinical trials: The promise and the caution. J Clin Oncol 29:606-609, 2011
13. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009
14. Thall PF, Logothetis C, Pagliaro LC, et al: Adaptive therapy for androgen-independent prostate cancer: A randomized selection trial of four regimens. J Natl Cancer Inst 99:1613-1622, 2007
15. Muss HB, Berry DA, Cirrincione CT, et al: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009
16. Thorpe KE, Zwarenstein M, Oxman AD, et al: A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers. J Clin Epidemiol 62:464-475, 2009
17. Concato J, Lawler EV, Lew RA, et al: Observational methods in comparative effectiveness research. Am J Med 123:e16-e23, 2010 (suppl 1)
18. Kushi LH, Doyle C, McCullough M, et al: American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 62:30-67, 2012
19. Domchek SM, Armstrong K, Weber BL: Clinical management of BRCA1 and BRCA2 mutation carriers. Nat Clin Pract Oncol 3:2-3, 2006
20. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
21. Norris S, Atkins D, Bruening W: Selecting observational studies for comparing medical interventions, in Methods Guide for Comparative Effectiveness Reviews. Rockville, MD, Agency for Healthcare Research and Quality, 2010, pp 4-6
22. Humphrey LL, Chan BK, Sox HC: Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137:273-284, 2002
23. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
24. Rosenbaum P, Rubin D: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983
25. Rosenbaum PR, Rubin DB: Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516-524, 1984
26. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281, 1998
27. Ganz PA, Kwan L, Stanton AL, et al: Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 29:1101-1109, 2011
28. Chen AB, Neville BA, Sher DJ, et al: Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol 29:2305-2311, 2011
29. Cleeland CS, Mendoza TR, Wang XS, et al: Levels of symptom burden during chemotherapy for advanced lung cancer: Differences between public hospitals and a tertiary cancer center. J Clin Oncol 29:2859-2865, 2011
30. O'Connor ES, Greenblatt DY, LoConte NK, et al: Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29:3381-3388, 2011
31. Punnen S, Cooperberg MR, Sadetsky N, et al: Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29:3510-3516, 2011
32. Wang SJ, Lemieux A, Kalpathy-Cramer J, et al: Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29:4627-4632, 2011
33. Wong YN, Mitra N, Hudes G, et al: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296:2683-2693, 2006
34. Litwin MS, Miller DC: Treating older men with prostate cancer: Survival (or selection) of the fittest? JAMA 296:2733-2734, 2006
35. Angrist JD, Imbens GW, Rubin DB: Identification of causal effects using instrumental variables. J Am Stat Assoc 91:444-455, 1996
36. Rassen JA, Brookhart MA, Glynn RJ, et al: Instrumental variables I: Instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol 62:1226-1232, 2009
37. Newhouse JP, McClellan M: Econometrics in outcomes research: The use of instrumental variables. Annu Rev Public Health 19:17-34, 1998
38. Lu-Yao GL, Albertsen PC, Moore DF, et al: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300:173-181, 2008
39. Wisnivesky JP, Halm E, Bonomi M, et al: Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med 181:264-269, 2010
40. Gore JL, Litwin MS, Lai J, et al: Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst 102:802-811, 2010
41. Hadley J, Yabroff KR, Barrett MJ, et al: Comparative effectiveness of prostate cancer treatments: Evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst 102:1780-1793, 2010
42. Saito AM, Landrum MB, Neville BA, et al: Hospice care and survival among elderly patients with lung cancer. J Palliat Med 14:929-939, 2011
43. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708-1717, 2011
44. Waldman M, Nicholson S, Adilov N: Does Television Cause Autism? Cambridge, MA, National Bureau of Economic Research, 2006
45. Whitehouse M: Is an economist qualified to solve puzzle of autism? Wall Street Journal, February 27, 2007:A1
46. Basu A, Heckman JJ, Navarro-Lozano S, et al: Use of instrumental variables in the presence of heterogeneity and self-selection: An application to treatments of breast cancer patients. Health Econ 16:1133-1157, 2007
47. Brooks JM, Chrischilles EA: Heterogeneity and the interpretation of treatment effect estimates from risk adjustment and instrumental variable methods. Med Care 45:S123-S130, 2007
48. Chang SM: The Agency for Healthcare Research and Quality (AHRQ) effective health care (EHC) program methods guide for comparative effectiveness reviews: Keeping up-to-date in a rapidly evolving field. J Clin Epidemiol 64:1166-1167, 2011
49. Harris RP, Helfand M, Woolf SH, et al: Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med 20:21-35, 2001
50. Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med 11:3-14, 2009
51. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001
52. Vandenbroucke JP, von Elm E, Altman DG, et al: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Ann Intern Med 147:W163-W194, 2007
53. Pauker SG, Kassirer JP: Decision analysis. N Engl J Med 316:250-258, 1987
54. Detsky AS, Naglie G, Krahn MD, et al: Primer on medical decision analysis: Part 1. Getting started. Med Decis Making 17:123-125, 1997
55. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253-1258, 1996
56. Detsky AS, Naglie G, Krahn MD, et al: Primer on medical decision analysis: Part 2. Building a tree. Med Decis Making 17:126-135, 1997
57. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
58. Krahn MD, Naglie G, Naimark D, et al: Primer on medical decision analysis: Part 4. Analyzing the model and interpreting the results. Med Decis Making 17:142-151, 1997
59. Garber AM, Phelps CE: Economic foundations of cost-effectiveness analysis. J Health Econ 16:1-31, 1997
60. Ito K, Elkin EB, Girotra M, et al: Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152:621-629, 2010
61. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: A decision-analysis model. N Engl J Med 324:160-168, 1991
62. Grann VR, Jacobson JS, Thomason D, et al: Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis. J Clin Oncol 20:2520-2529, 2002
63. Patient-Centered Outcomes Research Institute: Research methodology. http://www.pcori.org/what-we-do/methodology/
64. Hoomans T, Fenwick EA, Palmer S, et al: Value of information and value of implementation: Application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value Health 12:315-324, 2009
65. Claxton K: Bayesian approaches to the value of information: Implications for the regulation of new pharmaceuticals. Health Econ 8:269-274, 1999
66. Basu A, Meltzer D: Modeling comparative effectiveness and the value of research. Ann Intern Med 151:210-211, 2009